NasdaqGM:XNCRBiotechs
Xencor (XNCR) Updates Its Pipeline, Is The Stock Still Cheap?
Xencor (XNCR) stock moved after updated phase I data for XmAb819 in renal cell carcinoma supported dose selection and planning for a pivotal study, along with progress in XmAb942 and upcoming first-in-human testing of XmAb412.
See our latest analysis for Xencor.
Xencor’s recent clinical updates have arrived alongside sharp share price momentum, with a 1 day share price return of 8.72% and a 30 day share price return of 61.79%. The 1 year total shareholder return of 122.28% contrasts with...